336 related articles for article (PubMed ID: 27983764)
1. Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2
Mey UJ; Brugger W; Schwarb H; Pederiva S; Schwarzer A; Dechow T; Jehner P; Rauh J; Taverna CJ; Schmid M; Schmidt-Hieber M; Doerfel S; Fischer N; Ruefer A; Ziske C; Knauf W; Cathomas R; von Moos R; Hitz F; Sauter R; Hiendlmeyer E; Cantoni N; Bargetzi M; Driessen C
Br J Haematol; 2017 Mar; 176(5):770-782. PubMed ID: 27983764
[TBL] [Abstract][Full Text] [Related]
2. A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens.
Sanchez L; Vesole DH; Richter JR; Biran N; Bilotti E; McBride L; Anand P; Ivanovski K; Siegel DS
Br J Haematol; 2017 Feb; 176(3):440-447. PubMed ID: 27859001
[TBL] [Abstract][Full Text] [Related]
3. Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma.
Lazaryan A; Hussein MA; Reu FJ; Faiman B; Habecker B; Ann Karam M; Reed J; Hamilton K; Waksman J; Bruening K; Srkalovic G; Andresen S; Kalaycio M; Sweetenham JW; Sobecks R; Dean R; Knight R; Zeldis JB; Baz R
Am J Hematol; 2014 Apr; 89(4):349-54. PubMed ID: 24273135
[TBL] [Abstract][Full Text] [Related]
4. Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma.
Kumar SK; Krishnan A; LaPlant B; Laumann K; Roy V; Zimmerman T; Gertz MA; Buadi FK; Stockerl Goldstein K; Birgin A; Fiala M; Duarte L; Maharaj M; Levy J; Vij R
Am J Hematol; 2015 Dec; 90(12):1106-10. PubMed ID: 26331432
[TBL] [Abstract][Full Text] [Related]
5. "Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group.
Katodritou E; Vadikolia C; Lalagianni C; Kotsopoulou M; Papageorgiou G; Kyrtsonis MC; Matsouka P; Giannakoulas N; Kyriakou D; Karras G; Anagnostopoulos N; Michali E; Briasoulis E; Hatzimichael E; Spanoudakis E; Zikos P; Tsakiridou A; Tsionos K; Anargyrou K; Symeonidis A; Maniatis A; Terpos E
Ann Hematol; 2014 Jan; 93(1):129-39. PubMed ID: 23892921
[TBL] [Abstract][Full Text] [Related]
6. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.
Lentzsch S; O'Sullivan A; Kennedy RC; Abbas M; Dai L; Pregja SL; Burt S; Boyiadzis M; Roodman GD; Mapara MY; Agha M; Waas J; Shuai Y; Normolle D; Zonder JA
Blood; 2012 May; 119(20):4608-13. PubMed ID: 22451423
[TBL] [Abstract][Full Text] [Related]
7. Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide.
Lau IJ; Smith D; Aitchison R; Blesing N; Roberts P; Peniket A; Yong K; Rabin N; Ramasamy K
Ann Hematol; 2015 Apr; 94(4):643-9. PubMed ID: 25345871
[TBL] [Abstract][Full Text] [Related]
8. Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study.
Pozzi S; Gentile M; Sacchi S; Marcheselli R; Corso A; Cocito F; Musto P; Guarini A; Minoia C; Vincelli I; Ria R; Rivolti E; Mele G; Bari A; Mazzone C; Badiali S; Marcheselli L; Palumbo A; Morabito F
Leuk Lymphoma; 2017 Mar; 58(3):552-559. PubMed ID: 27442600
[TBL] [Abstract][Full Text] [Related]
9. Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077).
Beck J; Schwarzer A; Gläser D; Mügge LO; Uhlig J; Heyn S; Kragl B; Mohren M; Hoffmann FA; Lange T; Schliwa T; Zehrfeld T; Becker C; Kreibich U; Winkelmann C; Edelmann T; Andrea M; Bill M; Jentzsch M; Schwind S; Niederwieser D; Pönisch W
J Cancer Res Clin Oncol; 2017 Dec; 143(12):2545-2553. PubMed ID: 28828689
[TBL] [Abstract][Full Text] [Related]
10. Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077.
Pönisch W; Heyn S; Beck J; Wagner I; Mohren M; Hoffmann FA; Lange T; Schmalfeld M; Zehrfeld T; Schwarzer A; Winkelmann C; Edelmann T; Röhrborn R; Hebenstreit K; Al-Ali HK; Jäkel N; Niederwieser D
Br J Haematol; 2013 Jul; 162(2):202-9. PubMed ID: 23692564
[TBL] [Abstract][Full Text] [Related]
11. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom).
Knop S; Gerecke C; Liebisch P; Topp MS; Platzbecker U; Sezer O; Vollmuth C; Falk K; Glasmacher A; Maeder U; Einsele H; Bargou RC
Blood; 2009 Apr; 113(18):4137-43. PubMed ID: 19182205
[TBL] [Abstract][Full Text] [Related]
12. Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma.
Jimenez-Zepeda VH; Reece DE; Trudel S; Chen C; Tiedemann R; Kukreti V
Leuk Lymphoma; 2013 Mar; 54(3):555-60. PubMed ID: 22881043
[TBL] [Abstract][Full Text] [Related]
13. A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial.
Hou J; Du X; Jin J; Cai Z; Chen F; Zhou DB; Yu L; Ke X; Li X; Wu D; Meng F; Ai H; Zhang J; Wortman-Vayn H; Chen N; Mei J; Wang J
J Hematol Oncol; 2013 Jun; 6():41. PubMed ID: 23782711
[TBL] [Abstract][Full Text] [Related]
14. [A prospective multi-center trial of non-interventional and observational study of lenalidomide in Chinese patients with multiple myeloma].
Wang GM; Yang GZ; Huang ZX; Zhong YP; Jin FY; Liao AJ; Wang XM; Fu ZZ; Liu H; Li XL; Zhou JF; Zhang X; Hu Y; Meng FY; Huang XJ; Chen WM; Lu J
Zhonghua Nei Ke Za Zhi; 2017 Jul; 56(7):500-506. PubMed ID: 28693058
[No Abstract] [Full Text] [Related]
15. Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma.
Suzuki K; Handa H; Chou T; Ishizawa K; Takubo T; Kase Y
Int J Hematol; 2017 Apr; 105(4):445-452. PubMed ID: 28000099
[TBL] [Abstract][Full Text] [Related]
16. A phase II trial of small-dose bortezomib, lenalidomide and dexamethasone (sVRD) as consolidation/maintenance therapy in patients with multiple myeloma.
Ibata S; Sato T; Kuroda H; Nagamachi Y; Iyama S; Fujimi A; Kamihara Y; Konuma Y; Yoshida M; Tatekoshi A; Hashimoto A; Horiguchi H; Ono K; Murase K; Takada K; Miyanishi K; Kobune M; Hirayama Y; Kato J
Cancer Chemother Pharmacol; 2016 Nov; 78(5):1041-1049. PubMed ID: 27738809
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
Palumbo A; Gay F; Falco P; Crippa C; Montefusco V; Patriarca F; Rossini F; Caltagirone S; Benevolo G; Pescosta N; Guglielmelli T; Bringhen S; Offidani M; Giuliani N; Petrucci MT; Musto P; Liberati AM; Rossi G; Corradini P; Boccadoro M
J Clin Oncol; 2010 Feb; 28(5):800-7. PubMed ID: 20048187
[TBL] [Abstract][Full Text] [Related]
18. Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma.
Palumbo A; Larocca A; Falco P; Sanpaolo G; Falcone AP; Federico V; Canepa L; Crugnola M; Genuardi M; Magarotto V; Petrucci MT; Boccadoro M
Leukemia; 2010 May; 24(5):1037-42. PubMed ID: 20376079
[TBL] [Abstract][Full Text] [Related]
19. Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study.
Iida S; Nagai H; Kinoshita G; Miyoshi M; Robbins M; Pandya D; Bleickardt E; Chou T
Int J Hematol; 2017 Mar; 105(3):326-334. PubMed ID: 27848182
[TBL] [Abstract][Full Text] [Related]
20. Generic Lenalidomide Rivelime Versus Brand-name Revlimid® in the Treatment of Relapsed/Refractory Multiple Myeloma: A Retrospective Single-center Experience on Efficacy, Safety and Survival Outcome.
Beksac M; Seval GC; Koyun D; Topcuoglu P; Yuksel MK; Gurman G; Ilhan O
Clin Lymphoma Myeloma Leuk; 2023 Mar; 23(3):e164-e170. PubMed ID: 36610852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]